A Phase 1 Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, 2-cohort, multiple dose, fixed-sequence, DDI study
in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of
ATI-2173 in combination with tenofovir disoproxil fumarate and assessed for safety and
tolerability including blood tests to show how the body metabolizes and eliminates the
investigational drug as well as how the investigational drug interacts with tenofovir
disoproxil fumarate.